Cancer Stock and other viruses...

[Dude]

The stock is PPHM.. It is a biotech and we all know that biotechs are long shots but since were all gamblers here it is definitely worth a shot..
They have this new drug called Tarvacin. it is a novel approach to treating cancer and other viruses out there... They just entered phase 1 for cancer trials and are trying to get approval for hepatitis C.. So far this thing has worked tremendously in animal models for treating cancer,hepatitis C,Ebola,Marburg, and they are testing it against HIV as we speak.. Here is part of a news release they had on 4/18



Tarvacin(TM) Equivalent (3G4) Plus Radiation Reduces Lung Tumor Growth By Over 95%
Monday April 18, 8:30 am ET <TABLE height=4 cellSpacing=0 cellPadding=0 border=0><TBODY><TR><TD height=4></TD></TR></TBODY></TABLE>- Additional presentations at AACR show significant potential for Tarvacin(TM) in combination with chemotherapy or radiation therapy

TUSTIN, Calif., April 18 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM - News) reported that data will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Anaheim, California today related to Tarvacin(TM), its lead Anti-Phospholipid Therapy agent. The data to be presented shows that 3G4, the mouse version of Tarvacin(TM), is active against a number of solid tumors including lung, prostate, pancreatic, fibrosarcoma and breast cancers given as a single agent or in combination with either chemotherapy or radiation therapy. In a pre-clinical lung cancer model, the combination of 3G4 plus radiation therapy inhibited tumor growth by over 95% and 3G4 alone decreased tumor growth by 62%. In pancreatic pre-clinical tumor therapy experiments, 3G4 plus the chemotherapeutic agent gemcitabine decreased primary tumor growth by 60% and essentially stopped metastasis to liver and lymph nodes.


It is a long shot.. But if it does work who knows where this thing could go..

 

[Glaken]

Thanks for posting this Dude ...... very interesting. Where exactly does this land on the FDA radar? ..... I believe if it is in the pre-clinical stage they have to have a certain approval at some level to proceed with clinicals...I guess what I'm trying to ask is are they in the process of filing the paperwork or are they waiting for clinical approval?

Take Care, G

 

[Dude]

Glaken

Here is the deal.. They just started phase 1 trial for Cancer... It took about 8 months for the FDA to approve it because it was such a new approach to treating cancer..
About 2 months ago they filed the paper work for Hepatitis C....The FDA then approved that application 3 weeks ago.. So they will be starting phase 1 for hepatitis c in a month or so..
Next week they are at this huge Conference in Philly called the "BIO" Conference... People from all over the world will be there and at this point I am pretty confident that they will present there test results on HIV in monkeys.... and from what I am hearing it is pretty impressive stuff..
I also believe that the Dept of Defense is all over them for the bio terror angle small pox, ebola and a host of others...
There are a few downsides for this company....One they have about 11 million in cash and to get thru trials it costs alot of money..
They have alot of shares outstanding and they keep doing deals with outside money management firms and they offer more shares at a discount price......
The management has been shaky at best and there track record for execution has been poor..
Do yourself a favor here is a link to there web site they presented at the Rodman and Renshaw conference yesterday.. Just click on the Rodman conference in the upper left hand corner of the web site to listen to there presentation.. The CEO gave it and defenitely could use some more presentation skills but some of the stuff he said is pretty impressive..
http://www.peregrineinc.com/

 

[Glaken]

Thanks Dude, I'll keep an eye on it....will probably throw a volume watch alarm on'em and see what happends. Good Luck, G





<TABLE class=yfnc_modtitlew1 cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR class=yfnc_modtitle1><TD><SMALL>PEREGRINE PHARMA INC (NasdaqSCPHM) </SMALL></TD><TD align=right> </TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=0 width=1 border=0><TBODY><TR><TD height=1><SPACER height="1" width="1" type="block"></TD></TR></TBODY></TABLE><TABLE class=yfnc_modtitlew1 cellSpacing=0 cellPadding=0 width=580 border=0><TBODY><TR><TD colSpan=5><TABLE cellPadding=1 width="100%"><TBODY><TR><TD>After Hours <SMALL>(RT-ECN)</SMALL>: 1.03

0.02 (1.90%)</TD></TR></TBODY></TABLE></TD></TR><TR vAlign=top><TD><TABLE class=yfncsumdatagrid cellSpacing=0 cellPadding=0 width=185 border=0><TBODY><TR vAlign=top><TD class=yfnc_datamodoutline1><TABLE cellSpacing=1 cellPadding=2 width="100%" border=0><TBODY><TR><TD class=yfnc_tablehead1 width="48%">Last Trade:</TD><TD class=yfnc_tabledata1><BIG>1.05</BIG></TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Trade Time:</TD><TD class=yfnc_tabledata1>4:00PM ET</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Change:</TD><TD class=yfnc_tabledata1>0.00 (0.00%)</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Prev Close:</TD><TD class=yfnc_tabledata1>1.05</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Open:</TD><TD class=yfnc_tabledata1>1.06</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Bid:</TD><TD class=yfnc_tabledata1>0.01<SMALL> x 100</SMALL></TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Ask:</TD><TD class=yfnc_tabledata1>9,000.00<SMALL> x 100</SMALL></TD></TR><TR><TD class=yfnc_tablehead1 width="48%">1y Target Est:</TD><TD class=yfnc_tabledata1>N/A</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></TD><TD noWrap width=5><SPACER height="1" width="5" type="block"></SPACER></TD><TD><TABLE class=yfncsumdatagrid cellSpacing=0 cellPadding=0 width=185 border=0><TBODY><TR vAlign=top><TD class=yfnc_datamodoutline1><TABLE cellSpacing=1 cellPadding=2 width="100%" border=0><TBODY><TR><TD class=yfnc_tablehead1 width="48%">Day's Range:</TD><TD class=yfnc_tabledata1>1.03 - 1.06</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">52wk Range:</TD><TD class=yfnc_tabledata1>0.88 - 1.96</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Volume:</TD><TD class=yfnc_tabledata1>700,428</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Avg Vol <SMALL>(3m)</SMALL>:</TD><TD class=yfnc_tabledata1>737,965</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Market Cap:</TD><TD class=yfnc_tabledata1>158.80M</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">P/E <SMALL>(ttm)</SMALL>:</TD><TD class=yfnc_tabledata1>N/A</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">EPS <SMALL>(ttm)</SMALL>:</TD><TD class=yfnc_tabledata1>-0.10</TD></TR><TR><TD class=yfnc_tablehead1 width="48%">Div Yield <SMALL>(ttm)</SMALL>:</TD><TD class=yfnc_tabledata1>N/A (N/A)</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></TD><TD noWrap width=5><SPACER height="1" width="5" type="block"></SPACER></TD><TD vAlign=center align=middle width=193> <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD height=1><SPACER height="1" width="1" type="block"></TD></TR></TBODY></TABLE><SMALL>1d 5d 3m 6m 1y 2y 5y max http://finance.yahoo.com/q/bc?s=PPHM&t=</SMALL><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD height=10><SPACER height="1" width="1" type="block"></SPACER></TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=6 width="99%" border=0><TBODY><TR><TD vAlign=center align=middle><SMALL>The Top 100 Information Technology Companies</SMALL></TD></TR></TBODY></TABLE>
</TD></TR></TBODY></TABLE></P><CENTER>

<SMALL>Add PPHM to Portfolio</SMALL>

<SMALL>Set Alert</SMALL>

<SMALL>Download Data</SMALL></CENTER>


<TABLE class=yfnc_modtitlew1 cellSpacing=0 cellPadding=0 width=580 border=0><TBODY><TR vAlign=top><TD class=yfnc_modtitlew2 width=270><TABLE class="" style="MARGIN: 0px 0px 5px" cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR class=yfnc_modtitle1><TD><SMALL>HEADLINES</SMALL></TD><TD align=right><SMALL>Change Display [ hide $$ edit ] </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial</TD></TR><TR><TD><SMALL>PR Newswire (Fri, Jun 10) </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>Peregrine Pharmaceuticals to Present at Rodman and Renshaw Techvest 2nd Annual Security & Connectivity Investor Conference</TD></TR><TR><TD><SMALL>PR Newswire (Wed, Jun 8) </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>Peregrine IDs Cotara Delivery Method</TD></TR><TR><TD><SMALL>AP (Wed, Jun 1) </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>Clinical Data Published in Neurosurgery Shows Peregrine Pharmaceuticals' Cotara(R) Holds Promise for Treating Brain Cancer</TD></TR><TR><TD><SMALL>PR Newswire (Wed, Jun 1) </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>Peregrine Gets OK for Tarvacin Study</TD></TR><TR><TD><SMALL>AP (Tue, May 31) </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>Peregrine Pharmaceuticals Receives FDA Clearance to Initiate Tarvacin(TM) Anti-Viral Clinical Trial</TD></TR><TR><TD><SMALL>PR Newswire (Tue, May 31) </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>Data Published in Cancer Research Shows That Tarvacin(TM) Equivalent Plus Docetaxel Inhibits Breast Tumor Growth by 93%</TD></TR><TR><TD><SMALL>PR Newswire (Mon, May 16) </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>PEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits</TD></TR><TR><TD><SMALL>EDGAR Online (Wed, May 11) </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>CEO of Peregrine Pharmaceuticals, Inc. Interviewed by ExecutivesCorner</TD></TR><TR><TD><SMALL>Market Wire (Tue, May 10) </SMALL></TD></TR></TBODY></TABLE><TABLE class=yfncnhl cellSpacing=0 cellPadding=0 border=0><TBODY><TR vAlign=top><TD class=yfncnhlbl rowSpan=2>•</TD><TD>Peregrine Pharmaceuticals Submits Tarvacin(TM) Anti-Viral Investigational New Drug Application</TD></TR><TR><TD><SMALL>PR Newswire (Thu, May 5) </SMALL></TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD align=middle>More Headlines for PPHM...</TD></TR></TBODY></TABLE>
<TABLE class="" cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR class=yfnc_modtitle1><TD><SMALL>REPORTS</SMALL></TD><TD align=right> </TD></TR></TBODY></TABLE><TABLE style="MARGIN-BOTTOM: 5px" cellSpacing=0 cellPadding=0 border=0><TBODY><TR><TD>PPHM Correlations Report Jun 16, 2005</TD></TR><TR><TD class=yfncAttr><SMALL>Jun 16 - KRS</SMALL></TD></TR></TBODY></TABLE><TABLE style="MARGIN-BOTTOM: 5px" cellSpacing=0 cellPadding=0 border=0><TBODY><TR><TD>PPHM Investment Climate Report Jun 16, 2005</TD></TR><TR><TD class=yfncAttr><SMALL>Jun 16 - KRS</SMALL></TD></TR></TBODY></TABLE><TABLE style="MARGIN-BOTTOM: 5px" cellSpacing=0 cellPadding=0 border=0><TBODY><TR><TD>PPHM Volatility Report Jun 16, 2005</TD></TR><TR><TD class=yfncAttr><SMALL>Jun 16 - KRS</SMALL></TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD align=middle colSpan=2>More Reports for PPHM...</TD></TR></TBODY></TABLE>
</TD><TD width=7><SPACER width="7" type="block"></SPACER></TD><TD class=yfnc_modtitlew2 align=middle width=270><!-- SpaceID=0 robot --><TABLE height=15 cellSpacing=0 cellPadding=0 border=0><TBODY><TR><TD height=15></TD></TR></TBODY></TABLE><TABLE class="" cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR class=yfnc_modtitle1><TD><SMALL>KEY STATISTICS</SMALL></TD><TD align=right> </TD></TR></TBODY></TABLE><TABLE class=yfnc_datamodoutline1 cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD><TABLE cellSpacing=1 cellPadding=2 width="100%" border=0><TBODY><TR><TD class=yfnc_tablehead1 width="50%">Forward P/E <SMALL>(1 yr)</SMALL>:</TD><TD class=yfnc_tabledata1>N/A</TD></TR><TR><TD class=yfnc_tablehead1 width="65%">P/S <SMALL>(ttm)</SMALL>:</TD><TD class=yfnc_tabledata1>26.94</TD></TR><TR><TD class=yfnc_tablehead1 width="65%">Dividend Date:</TD><TD class=yfnc_tabledata1>N/A</TD></TR><TR><TD class=yfnc_tablehead1 width="65%">Ex-Dividend Date:</TD><TD class=yfnc_tabledata1>N/A</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD vAlign=bottom align=middle height=20>More Key Statistics...</TD></TR></TBODY></TABLE>
<TABLE class="" cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR class=yfnc_modtitle1><TD><SMALL>ANALYST</SMALL></TD><TD align=right> </TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR><TD align=middle>No analyst data available for PPHM. </TD></TR></TBODY></TABLE>
<TABLE class="" cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR class=yfnc_modtitle1><TD><SMALL>BUSINESS SUMMARY</SMALL></TD><TD align=right> </TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=2 width="100%" border=0><TBODY><TR vAlign=top><TD>Peregrine Pharmaceuticals, Inc. engages in the research, development, manufacture, and commercialization of cancer therapeutics and cancer diagnostics through a series of platform technologies using monoclonal antibodies. more</TD></TR><TR><TD colSpan=3><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD class=yfnc_modulehr1 noWrap bgColor=#dcdcdc height=1><SPACER height="1" width="1" type="block" /></TD></TR></TBODY></TABLE></TD></TR><TR><TD align=middle colSpan=2>Company Profile - Industry</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></P>

 

[Dude]

Starting to make a move

PPHM closed today at 1.07 up 4 cents....... Was at 1.10 before they dropped it at the close on no volume.. Stock traded 2.7 million shares usual volume 700k... BIO conference ongoing.. They are presenting Wed.......... Looking for news on either Tues or Wed.........News could be of the variety of HIV data in monkeys or quite possibly Avian flu data...... People staring to panic because of Avian flu now being found in humans..... something to keep an eye on.................

 

[LEYKIS101]

Good info Dude, I will keep an eye out for that stock.

 

[Dude]

Starting to make a move...Article came out in Orange County Ca paper on Saturday... On Monday it traded 6 mill shares and was up 12 cents.. Today they announced that they are working with the military on Infectious diseases.. It closed today at 1.22 on over 3 mill shares.. I believe the 200 day MA is 1.22.. so if it closes above that tomorrow next week it could run.. Just my opinion.<META content="MSHTML 6.00.2900.2668" name=GENERATOR>

http://www.rednova.com/news/health/176637/tustin_company_thinks_new_drug_could_target_cancer_and_multiple/

 

[Dawoofdaddy]

Biotech sector very volatile invest with caution in smaller companies. Best of luck to those that buy this stock.

 

[Dude]

Update

Stock closed at 1.16 Friday up 15 cents for the week.. Traded 16 mill shares for the week. Normal volume for the week is 4 mill.
They have been testing it in animals for Avian Flu and Hiv and I expect them to announce those findings in the next few weeks....If any of you have paid attention in the last few weeks several stocks have taken off on Avian Flu data..... They are also announcing on Feb 27 there progress in Phase 1 for Hep C.... For those of you who dont know Phase 1 trials are just for the drugs Toxicity levels.. So if they even hint at the drug being effective in reducing Hep C levels in Phase 1 it could take off.......Just a heads up and as always do your own research...

 

[Dude]

Breaking out

Today on no news..... Now at 1.34 up 14 cents on 9 million traded.. avg trading day is 800K ......... Still has a long ways to go.........

 

[GoCreighton]

go go go!

 

[UoweDucks]

Here is a cancer play..

YMI
YM Biosciences

The big drug in trials is tesmilifene vs breast cancer. I have Been in since mid 2's would look to exit in 5's. Sanofi just signed a collaborative agreement with them which has pushed it into the 3's... Still buying.

__________________________________
YM BioSciences, Inc., a development stage biopharmaceutical company, engages in the research and development of products primarily for the treatment of cancer. Its product candidates in the clinical stage of development include Tesmilifene, Nimotuzumab, AeroLEF, Norelin, and Radiotheracim. Tesmilifene, which is in phase III clinical trial, is a small molecule chemopotentiator for the treatment of metastatic and recurrent breast cancer. Nimotuzumab, which is in phase II clinical trial, is an antiepidermal growth factor humanized monoclonal antibody for the treatment of epithelial cancers. AeroLEF, which is in phase II clinical trials, is a proprietary formulation of both free and liposome-encapsulated fentanyl administered by pulmonary inhalation, is being developed for the treatment of severe and moderate acute pain and cancer pain. Norelin is a phase II clinical trial product for the treatment of sex-hormone dependent cancers. Radiotheracim is a radiolabelled humanized monoclonal antibody, targeting the epidermal growth factor receptor, and is being developed for the treatment of brain cancers. The company also has a portfolio of preclinical compounds shown to act as chemopotentiators while protecting normal cells. YM BioSciences has a collaborative agreement with Sanofi-Aventis to investigate the effect of combining tesmilifene and docetaxel for the treatment of women with rapidly progressing metastatic breast cancer. The company was founded in 1994 and is headquartered in Mississauga, Canada.

 

[Dude]

Still Moving.

PPHM up another .22 cents today to 1.54 on no news announcement.. this thing is finally being accumulated by the big boys........ Still loooking for news...... Now up over 50% last 2 weeks......10 cents off 52 week high........

 

[UoweDucks]

YMI has been moving

Now up to 4.30...

Money is really coming in on this stock... Would not be buying anymore here as it is approaching my forward earnings price target...

 

[UoweDucks]

Not sure anyone cares on this but since I posted the stock has been on fire...

I am am still holding on to my shares and this is why:


<TABLE class=STORYHEADER cellSpacing=0 cellPadding=0><TBODY class=STORYBODY><TR class=STORYODD WIDTH="100%"><TD class=STORYNAME align=left>( DJ ) 02/13 09:33AM DJ YM BioSciences Gets FDA Fast Track Status For Tesmilifene </TD></TR></TBODY></TABLE><TABLE class=STORYTEXT cellSpacing=0 cellPadding=0><TBODY class=STORYBODY><TR class=STORYEVEN><TD class=STORY colSpan=6>
NEW YORK (Dow Jones)--YM BioSciences Inc. (YMI) said the Food and Drug Administration granted fast-track designation to its lead drug candidate, tesmilifene. The Mississauga, Ontario, drug development company said the designation covered tesmilifene in combination with an anthracycline chemotherapeutic as a treatment for advanced breast cancer. The company is still seeking clarification from the FDA on certain aspects of the letter. Shortly after the opening bell, American Stock Exchange-listed shares of YM BioSciences traded at $5.80, up 77 cents, or 15.3%, on volume of 9,500 shares. Average volume is 140,000 shares a day. </PRE></TD></TR></TBODY></TABLE></P>

 

[pops69]

i remember having gnlb, which was on fast track 3rd stage testing, vs 1st stage, they were flying high in the 20's, but like most drugs fail some fda approval along the way, now they just had a revese stocks split of about 1-20 and trading at 2.16

watch your back side on these, cause they go down much faster than up, cause you wont get the news first.

glta

 

[UoweDucks]

watch your back side on these, cause they go down much faster than up, cause you wont get the news first.

glta

True words. Biotechs are a very fun (risky) sector to invest in during the early stages. Companies like these almost never bring their drugs to market however as they don't have the $$ to market the drug... If the trials result in success a buyout is coming.

 

[terrygd]

Anti-Viral Agent Tarvacin(TM) is Safe and Well-Tolerated in HCV Patients

Clinical Trial Results Show that Peregrine's First-In-Class Anti-Viral Agent Tarvacin(TM) is Safe and Well-Tolerated in HCV Patients
Monday February 27, 7:00 am ET <TABLE height=4 cellSpacing=0 cellPadding=0 border=0><TBODY><TR><TD height=4></TD></TR></TBODY></TABLE>- First Human Data Demonstrating the Safety of Tarvacin(TM) Will Be Presented Today at the 2nd Annual 'Viral Hepatitis in Drug Discovery and Development' Conference -
BOSTON and TUSTIN, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it will present top line data demonstrating that its first-in-class anti-viral compound Tarvacin(TM) Anti-Viral appeared safe and well-tolerated in a Phase l study in chronic hepatitis C virus (HCV) infected patients. Initial results from the Phase l study will be presented at 1:50 pm EST today at the Strategic Research Institute's 2nd Annual "Viral Hepatitis in Drug Discovery and Development" conference in Boston.
<TABLE cellSpacing=4 cellPadding=4 align=left border=0><TBODY><TR><TD><TABLE cellSpacing=0 cellPadding=0 border=0><TBODY><TR><TD align=middle>[SIZE=-2]ADVERTISEMENT[/SIZE]
<IFRAME style="WIDTH: 300px; HEIGHT: 2px" marginWidth=0 marginHeight=0 src="http://view.atdmt.com/INV/iview/yhxxxfsi0050000071inv/direct/01/?time=1141058060580608&click=http://us.ard.yahoo.com/SIG=12dui00k6/M=388198.7676784.8617687.1383221/D=fin/S=7811758:LREC/Y=YAHOO/EXP=1141065260/A=3209923/R=0/*" frameBorder=0 width=300 scrolling=no height=250 allowTransparency leftmargin="0" topmargin="0"><script language="JavaScript" type="text/javascript">document.write(' ');</script><noscript> </noscript></IFRAME>

</TD></TR></TBODY></TABLE><SCRIPT type=text/javascript>if (window.yzq_a == null) document.write("<scr" + "ipt type=text/javascript src=""http://us.js2.yimg.com/us.js.yimg.com/lib/bc/bc_1.7.3.js></scr" + "ipt>");</SCRIPT><SCRIPT type=text/javascript>if (window.yzq_a){yzq_a('p', 'P=S2C6SthtfJCOhrOwQ_46KAbnQ6G4vkQDKgwAAV6z&T=1cqr3rl3l%2fX%3d1141058060%2fE%3d7811758%2fR%3dfin%2fK%3d5%2fV%3d1.1%2fW%3d8%2fY%3dYAHOO%2fF%3d2737659431%2fH%3dY29icmFuZD0iPGEgaHJlZj1odHRwOi8vd3d3LnBybmV3c3dpcmUuY29tL3lhaG9vLz48aW1nIGJvcmRlcj0wIHNyYz1odHRwOi8vdXMuaTEueWltZy5jb20vdXMueWltZy5jb20vaS91cy9maS9nci9wYXJ0bmVyX2xvZ29zL3BybmV3c3dpcmVfMTcweDMzX2xvZ28uZ2lmIGFsdD1QUl9OZXdzd2lyZT48L2E.IiBjYWNoZWhpbnQ9Ijc4MTE3NTgiIGNhY2hlaGludD0iNzgxMTc1OCI-%2fS%3d1%2fJ%3d8E7C6DD8');yzq_a('a', '&U=139g0f26n%2fN%3dCLK1FNhtfGA-%2fC%3d388198.7676784.8617687.1383221%2fD%3dLREC%2fB%3d3209923');}</SCRIPT><NOSCRIPT>

</NOSCRIPT></TD></TR></TBODY></TABLE>Tarvacin Anti-Viral is the first in a new class of anti-phosphotidylserine (PS) immunotherapeutics that targets and binds to cellular components that are normally not present on the outside of cells, but which become exposed on certain virally infected cells and on the surface of enveloped viruses. Tarvacin helps stimulate the body's immune defenses to destroy both the virus particles and the infected cells.
The primary goals of the Phase l study were to determine the safety profile and distribution properties of Tarvacin in patients with chronic hepatitis C viral infections. The data will support initiation of repeat dose and combination therapy trials that the company expects to begin later this year. In the ascending, single dose trial, 24 patients with chronic HCV who had either failed or who no longer responded to standard-of-care treatment were administered Tarvacin Anti-Viral. The drug was well tolerated, with no serious adverse events reported at any of the four dose levels tested, and no potential dose limiting toxicities were observed. Reported adverse events were mild, infrequent, transient and likely not drug-related.
"Demonstrating the safety of the new approach is a critical step in developing a first-in-class therapeutic, so this Phase l data indicating that Tarvacin appears to be safe and well-tolerated is a key milestone for the program," said Steven W. King, president and CEO of Peregrine. "Completing this study ahead of schedule with the safety profile observed should help us to expedite advancing the Tarvacin Anti-Viral HCV clinical program into repeat dose and combination therapy studies this year."
Tarvacin Anti-Viral has shown promise in preclinical studies in a variety of anti-viral and biodefense applications. Anti-PS agents attach to phospholipids found on the surface of virus particles, including HCV, influenza and other virus strains, as well as on the outer surface of human host cells infected with these viruses. Anti-PS immunotherapeutics are believed to work by helping stimulate the body's natural immune defenses to destroy both virus particles and infected cells. The targeted phospholipids are not exposed on healthy cells, which are therefore not affected by anti-PS agents. Since the targeted phospholipids are derived from the host rather than from the virus itself, anti-PS immunotherapeutics are expected to have broad activity against a variety of virus strains and to be less subject to the development of anti-viral drug resistance.
"Tarvacin represents a completely new approach to treating HCV infections, and these initial positive safety data are promising," said Dr. Eliot W. Godofsky, principal investigator of the Phase l study. "While there are a number of new HCV drugs in development, Tarvacin's unique mechanism has the potential to combat the virus in a novel way. In addition, it's potential for use in combination regimens to control and ultimately cure HCV warrants further investigation."
Single administration of anti-viral agents is not generally expected to have a significant effect on HCV viral titers as a result of rapid virus production and turnover. However viral titer data are being collected as part of the Tarvacin study design and are currently being analyzed. These data will be discussed in an appropriate future scientific forum along with final safety data from the Phase I trial.
Based on the good safety observed in the highest dose of Tarvacin tested, Peregrine may assess one additional dose level by adding another cohort to the existing HCV study through a protocol amendment. This addition is not expected to affect the timing of the new studies now being planned. Similar to their anti-viral mechanism, anti-PS immunotherapeutics also bind to phospholipids exposed on tumor blood vessels in all solid cancers tested to date, and they have shown promise in a number of preclinical cancer models. Tarvacin Anti-Cancer is in Phase l clinical trials for the treatment of advanced refractory solid tumor cancers.

 

[Dude]

Ok Guys been Patiently waiting for sometime and this thing finally broke out to new high's today.. up 27 cents from 1.56 to 1.83... on no news announcement.... The word still isnt out on what they have going for them although they did have a news release last week on how there experimental drug completely stopped Avian/Bird flu in chicken eggs. So now it is grouped into the Bird Flu group of stocks and any negative happenings overseas with bird flu and this thing will get some play..
But the bottom line is they are going to be entering into the next Phase for Hepatitis C, They have been in Phase 1 for Cancer for about a year, Word is coming Hopefully soon that they will enter Phase 1 for HIV with a world renowned Scientist doing the study.. All of these trials with just one drug...........The stock is still cheap and the world and the public still arent aware of it.

 

[Dude]

on a side note there P.R firm is Gendell-Lindheim gendell used to work for CNBC as there top medical correspondent so he still has connections.. might be awhile before they hit CNBC but what better kind of exposure do u need.